Astrotech Corporation · NASDAQ:ASTC
Astrotech — Investor Presentation (June 2017)
16 slides from Astrotech's investor presentation, Jun 14, 2017
Slide 1: Investor Presentation June 2017
Investor Presentation June 2017
Slide 2: Safe Harbor
2 Safe Harbor Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectatio
Slide 3: Designs and builds business enterprises around extraordinary opportunities
Designs and builds business enterprises around extraordinary opportunities.
Slide 4: Proven Value Creation for Shareholders
4 • Restructured balance sheet to avoid bankruptcy • Converted $65 million in debt to equity • Streamlined operations to focus on most promising initiatives • Set up Astrotech Space Operations (ASO) as an easy carve-out • Launched 1st Detect and Astrogenetix • Improved profitability • Increased pric
Slide 5: Making the World Safer: 1st Detect
MAKING THE WORLD SAFER Develops, manufactures, and sells chemical analyzers for government and commercial markets. May 10, 2017 – Astrotech announced that it has engaged Chardan to pursue strategic alternatives for 1st Detect, including the sale of the subsidiary.
Slide 6: Breakthrough in Low-Cost Chemical Detection
• Disruptive technology • Performance far exceeds leading competing technology, Ion Mobility Spectrometry (IMS) • Performance on par with traditional lab mass spectrometers • Low cost • Over $40 million invested • Validation • Awarded the Department of Homeland Security’s next-generation ETD develop
Slide 7: Large Markets with Differentiated Solutions
• Explosives Trace Detector (ETD) market • Of the 25,000 ETDs currently deployed, 22,000 are outdated and ready for replacement • Growing market driven by terrorist threats and vulnerability of key targets • Currently preparing for TSL testing Large Markets with Differentiated Solutions 7 TRACER 100
Slide 8: Robust Intellectual Property Portfolio
29 PATENTS AWARDED* Robust Intellectual Property Portfolio 8 1. Driving an ion trap mass spectrometer or mass filter 2. End cap voltage control of ion traps 3. Mass Spectrometer Ion Trap Having Assymetric End Cap Apertures 4. End cap voltage control of ion traps (Continuation) 5. Systems and Methods
Slide 9: 1st Detect Provides the TSA Solution
1st Detect is ideally positioned to disrupt the ETD Market. • TSA has disclosed that they are seeking more capable ETD instrumentation (DHS BAA 13-03) • Enhanced trace detection capabilities • Increased throughput • Increased detection limits • Decreased false alarm rate • Instant threat library upd
Slide 10: Digitizes, restores, enhances, and optimizes media across the entertainment industry
Digitizes, restores, enhances, and optimizes media across the entertainment industry.
Slide 11: Leading Digital Image Correction & Enhancement (ICE)
11 Leading Digital Image Correction & Enhancement (ICE) Astral Black ICE™Astral Color ICE™ Astral HDR ICE™ Digital ICE® proprietary technology uses intelligent algorithms, originally developed by IBM and Eastman Kodak to remove defects such as scratches, dust, and lint from film.
Slide 12: Another Breakthrough Technology
• Disruptive technology ahead of market • Dramatically reducing cost and time through automation and proprietary software • Competition uses expensive and time-consuming manual process • Increasing traction • Most major studios have reviewed or are reviewing technology • Excellent feedback • Signifi
Slide 13: Maintaining Artistic Integrity, Selected by Industry Leaders
Maintaining Artistic Integrity, Selected by Industry Leaders 13
Slide 14: Saving lives on earth by developing products in space
Savings lives on earth by developing products in space.
Slide 15: Developing Vaccines
Developing Vaccines • Flew 12 biomarker missions to the International Space Station (ISS) • Funded by NASA and working with the University of Maryland Center of Vaccine Development • Continuing pursuit of an FDA Investigational New Drug (IND) application for Salmonella • Requiring minimal investment
Slide 16: Financial Highlights
Financial Highlights Continuing conservative cost management. • Expect $3.5M in savings through FY 2017 from July 2016 corporate realignment • Cash burn rate of ~$1M per month Maintaining a healthy balance sheet at March 31, 2017. • $17.4M in cash and investments • No debt Aligned interests with sha